Thurston Springer Miller Herd & Titak Inc. Has $2.59 Million Position in Johnson & Johnson (NYSE:JNJ)

Thurston Springer Miller Herd & Titak Inc. increased its stake in shares of Johnson & Johnson (NYSE:JNJFree Report) by 35.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,888 shares of the company’s stock after purchasing an additional 4,661 shares during the quarter. Thurston Springer Miller Herd & Titak Inc.’s holdings in Johnson & Johnson were worth $2,587,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in shares of Johnson & Johnson during the second quarter valued at about $1,082,000. Cranbrook Wealth Management LLC boosted its position in Johnson & Johnson by 157.0% during the 2nd quarter. Cranbrook Wealth Management LLC now owns 4,847 shares of the company’s stock worth $708,000 after buying an additional 2,961 shares during the period. Financial & Tax Architects LLC grew its holdings in Johnson & Johnson by 11.9% during the 2nd quarter. Financial & Tax Architects LLC now owns 39,362 shares of the company’s stock worth $5,753,000 after acquiring an additional 4,189 shares during the last quarter. E Fund Management Co. Ltd. raised its stake in shares of Johnson & Johnson by 12.2% during the second quarter. E Fund Management Co. Ltd. now owns 16,173 shares of the company’s stock valued at $2,364,000 after acquiring an additional 1,755 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV lifted its holdings in shares of Johnson & Johnson by 3.9% during the second quarter. Mercer Global Advisors Inc. ADV now owns 695,805 shares of the company’s stock worth $92,799,000 after purchasing an additional 26,174 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of several analyst reports. Wolfe Research initiated coverage on Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Royal Bank of Canada raised their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Citigroup reduced their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Morgan Stanley raised their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Finally, Guggenheim upped their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $174.71.

Read Our Latest Research Report on Johnson & Johnson

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $144.74 on Thursday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The business has a 50-day simple moving average of $149.12 and a 200 day simple moving average of $156.09. The firm has a market capitalization of $348.48 billion, a price-to-earnings ratio of 20.95, a PEG ratio of 2.52 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same period in the prior year, the firm earned $2.66 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.2% on a year-over-year basis. On average, research analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.43%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.